Bourque, D., Pomerleau, Y
The thioredoxin encoded by the rod-derived cone viability factor gene protects cone photoreceptors against oxidative stress
TRIUMPH Phase 3 Trial Program Full breakdown of every TRIUMPH arm, doses, endpoints, and what each trial is designed to support on the eventual label
While not yet FDA-approved for liver conditions, these agents improve metabolic parameters that influence hepatic health
Researchers have safely applied these doses for up to two weeks based on the available case reports [6, 8, 14]
Semaglutide, a GLP-1 receptor agonist, stands out among these treatments due to its unique mechanism of action, efficacy, and benefits beyond glycemic control